Cargando…
Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells
The transcription factor FOXO3 is associated with poor outcome in high-stage neuroblastoma (NB), as it facilitates chemoprotection and tumor angiogenesis. In other tumor entities, FOXO3 stimulates metastasis formation, one of the biggest challenges in the treatment of aggressive NB. However, the imp...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017090/ https://www.ncbi.nlm.nih.gov/pubmed/31861249 http://dx.doi.org/10.3390/cells9010001 |
_version_ | 1783497123338125312 |
---|---|
author | Salcher, Stefan Spoden, Gilles Huber, Julia M. Golderer, Georg Lindner, Herbert Ausserlechner, Michael J. Kiechl-Kohlendorfer, Ursula Geiger, Kathrin Obexer, Petra |
author_facet | Salcher, Stefan Spoden, Gilles Huber, Julia M. Golderer, Georg Lindner, Herbert Ausserlechner, Michael J. Kiechl-Kohlendorfer, Ursula Geiger, Kathrin Obexer, Petra |
author_sort | Salcher, Stefan |
collection | PubMed |
description | The transcription factor FOXO3 is associated with poor outcome in high-stage neuroblastoma (NB), as it facilitates chemoprotection and tumor angiogenesis. In other tumor entities, FOXO3 stimulates metastasis formation, one of the biggest challenges in the treatment of aggressive NB. However, the impact of FOXO3 on the metastatic potential of neuronal tumor cells remains largely unknown. In the present study, we uncover the small leucine-rich proteoglycan family member lumican (LUM) as a FOXO3-regulated gene that stimulates cellular migration in NB. By a drug-library screen we identified the small molecular weight compound repaglinide (RPG) as a putative FOXO3 inhibitor. Here, we verify that RPG binds to the FOXO3-DNA-binding-domain (DBD) and thereby silences the transcriptional activity of FOXO3. Consistent with the concept that the FOXO3/LUM axis enhances the migratory capacity of aggressive NB cells, we demonstrate that stable knockdown of LUM abrogates the FOXO3-mediated increase in cellular migration. Importantly, FOXO3 inhibition by RPG represses the binding of FOXO3 to the LUM promoter, inhibits FOXO3-mediated LUM RNA and protein expression, and efficiently abrogates FOXO3-triggered cellular “wound healing” as well as spheroid-based 3D-migration. Thus, silencing the FOXO3/LUM axis by the FDA-approved compound RPG represents a promising strategy for novel therapeutic interventions in NB and other FOXO3-dependent tumors. |
format | Online Article Text |
id | pubmed-7017090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70170902020-02-28 Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells Salcher, Stefan Spoden, Gilles Huber, Julia M. Golderer, Georg Lindner, Herbert Ausserlechner, Michael J. Kiechl-Kohlendorfer, Ursula Geiger, Kathrin Obexer, Petra Cells Article The transcription factor FOXO3 is associated with poor outcome in high-stage neuroblastoma (NB), as it facilitates chemoprotection and tumor angiogenesis. In other tumor entities, FOXO3 stimulates metastasis formation, one of the biggest challenges in the treatment of aggressive NB. However, the impact of FOXO3 on the metastatic potential of neuronal tumor cells remains largely unknown. In the present study, we uncover the small leucine-rich proteoglycan family member lumican (LUM) as a FOXO3-regulated gene that stimulates cellular migration in NB. By a drug-library screen we identified the small molecular weight compound repaglinide (RPG) as a putative FOXO3 inhibitor. Here, we verify that RPG binds to the FOXO3-DNA-binding-domain (DBD) and thereby silences the transcriptional activity of FOXO3. Consistent with the concept that the FOXO3/LUM axis enhances the migratory capacity of aggressive NB cells, we demonstrate that stable knockdown of LUM abrogates the FOXO3-mediated increase in cellular migration. Importantly, FOXO3 inhibition by RPG represses the binding of FOXO3 to the LUM promoter, inhibits FOXO3-mediated LUM RNA and protein expression, and efficiently abrogates FOXO3-triggered cellular “wound healing” as well as spheroid-based 3D-migration. Thus, silencing the FOXO3/LUM axis by the FDA-approved compound RPG represents a promising strategy for novel therapeutic interventions in NB and other FOXO3-dependent tumors. MDPI 2019-12-18 /pmc/articles/PMC7017090/ /pubmed/31861249 http://dx.doi.org/10.3390/cells9010001 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Salcher, Stefan Spoden, Gilles Huber, Julia M. Golderer, Georg Lindner, Herbert Ausserlechner, Michael J. Kiechl-Kohlendorfer, Ursula Geiger, Kathrin Obexer, Petra Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells |
title | Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells |
title_full | Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells |
title_fullStr | Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells |
title_full_unstemmed | Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells |
title_short | Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells |
title_sort | repaglinide silences the foxo3/lumican axis and represses the associated metastatic potential of neuronal cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017090/ https://www.ncbi.nlm.nih.gov/pubmed/31861249 http://dx.doi.org/10.3390/cells9010001 |
work_keys_str_mv | AT salcherstefan repaglinidesilencesthefoxo3lumicanaxisandrepressestheassociatedmetastaticpotentialofneuronalcancercells AT spodengilles repaglinidesilencesthefoxo3lumicanaxisandrepressestheassociatedmetastaticpotentialofneuronalcancercells AT huberjuliam repaglinidesilencesthefoxo3lumicanaxisandrepressestheassociatedmetastaticpotentialofneuronalcancercells AT golderergeorg repaglinidesilencesthefoxo3lumicanaxisandrepressestheassociatedmetastaticpotentialofneuronalcancercells AT lindnerherbert repaglinidesilencesthefoxo3lumicanaxisandrepressestheassociatedmetastaticpotentialofneuronalcancercells AT ausserlechnermichaelj repaglinidesilencesthefoxo3lumicanaxisandrepressestheassociatedmetastaticpotentialofneuronalcancercells AT kiechlkohlendorferursula repaglinidesilencesthefoxo3lumicanaxisandrepressestheassociatedmetastaticpotentialofneuronalcancercells AT geigerkathrin repaglinidesilencesthefoxo3lumicanaxisandrepressestheassociatedmetastaticpotentialofneuronalcancercells AT obexerpetra repaglinidesilencesthefoxo3lumicanaxisandrepressestheassociatedmetastaticpotentialofneuronalcancercells |